Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience

BMC Gastroenterology

Research Article

Takuya Yoshino¹  Hiroshi Nakase¹  Yusuke Honzawa¹  Yoshihisa Tsuji¹  Naoki Minami¹  Satoshi Yamada¹  Minoru Matsuura¹  Takahiko Toyonaga² 

[1] Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, 606-8507, Sakyo-ku, Kyoto, Japan;The Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan;

关键词: Ulcerative colitis;    Infliximab;    Immunomodulator;    Infliximab intensification;   

DOI  :  10.1186/1471-230X-14-80

 received in 2013-12-11, accepted in 2014-04-16,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundThe long-term efficacy of infliximab (IFX) for patients with refractory ulcerative colitis (UC) is unclear. The aim of this study was to assess the long-term outcomes of IFX treatment in patients with refractory UC.MethodsThirty-three patients with refractory UC who received IFX treatment at Kyoto University Hospital between 2003 and 2013 were retrospectively evaluated. IFX intensification was defined as a dose escalation (up to 10 mg/kg) and/or shorter intervals between infusions (every 4–6 weeks).ResultsOf the 33 patients who received scheduled infusions of IFX, 24 (72.7%) achieved clinical remission within 8 weeks after initiating IFX treatment. Of these 24 responders, 17 (70.8%) experienced a relapse of UC and required IFX intensification, and 16 (66.7%) eventually maintained clinical remission with IFX treatment, including IFX intensification. Of the 33 patients, 6 (18.2%) underwent colectomy during IFX treatment. Multivariate regression analysis showed that a serum C-reactive protein (CRP) concentration <5 mg/L two weeks after starting IFX was a predictor of a positive clinical response to IFX induction therapy. No severe adverse events occurred in UC patients treated with IFX.ConclusionIFX intensification was necessary for long-term maintenance of remission and to prevent colectomy in patients with refractory UC.

【 授权许可】

Unknown   
© Yamada et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.